These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14973114)

  • 1. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.
    Simeone AM; Li YJ; Broemeling LD; Johnson MM; Tuna M; Tari AM
    Cancer Res; 2004 Feb; 64(4):1224-8. PubMed ID: 14973114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
    Simeone AM; Broemeling LD; Rosenblum J; Tari AM
    Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
    Hsu AL; Ching TT; Wang DS; Song X; Rangnekar VM; Chen CS
    J Biol Chem; 2000 Apr; 275(15):11397-403. PubMed ID: 10753955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD; Kao MC; Lin JK
    J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells.
    Lim SJ; Gutiérrez-Puente Y; Tari AM
    Tumour Biol; 2002; 23(5):279-86. PubMed ID: 12595744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.
    Levitt RJ; Pollak M
    Cancer Res; 2002 Dec; 62(24):7372-6. PubMed ID: 12499282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.
    Kulp SK; Yang YT; Hung CC; Chen KF; Lai JP; Tseng PH; Fowble JW; Ward PJ; Chen CS
    Cancer Res; 2004 Feb; 64(4):1444-51. PubMed ID: 14973075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
    Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
    Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide.
    Simeone AM; Ekmekcioglu S; Broemeling LD; Grimm EA; Tari AM
    Mol Cancer Ther; 2002 Oct; 1(12):1009-17. PubMed ID: 12481423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
    Totzke G; Schulze-Osthoff K; Jänicke RU
    Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines.
    Honjo S; Osaki M; Ardyanto TD; Hiramatsu T; Maeta N; Ito H
    DNA Cell Biol; 2005 Mar; 24(3):141-7. PubMed ID: 15767780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
    Elder DJ; Halton DE; Hague A; Paraskeva C
    Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
    Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
    Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
    St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
    Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.
    Michael MS; Badr MZ; Badawi AF
    Int J Mol Med; 2003 Jun; 11(6):733-6. PubMed ID: 12736714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells.
    Wang TT; Phang JM
    Cancer Lett; 1996 Oct; 107(1):65-71. PubMed ID: 8913268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
    Simeone AM; Colella S; Krahe R; Johnson MM; Mora E; Tari AM
    Carcinogenesis; 2006 Mar; 27(3):568-77. PubMed ID: 16199439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways.
    Sánchez-Alcázar JA; Bradbury DA; Pang L; Knox AJ
    Lung Cancer; 2003 Apr; 40(1):33-44. PubMed ID: 12660005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3.
    Lai GH; Zhang Z; Sirica AE
    Mol Cancer Ther; 2003 Mar; 2(3):265-71. PubMed ID: 12657721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.